Chong Kun Dang Pharmaceutical Corp. - Company Profile
Powered by 
All the data and insights you need on Chong Kun Dang Pharmaceutical Corp. in one report.
$295
- Save hours of research time and resources with
our up-to-date Chong Kun Dang Pharmaceutical Corp. Strategy Report
- Understand Chong Kun Dang Pharmaceutical Corp. position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Chong Kun Dang Pharmaceutical Corp. patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| DK3515443T3 | Application | KOMBINERET SAMMENSÆTNING TIL FOREBYGGELSE ELLER BEHANDLING AF CANCER, SOM OMFATTER ET BENZOPHENONTHIAZOLDERIVAT SOM ET VDA OG EN TOPOISOMERASE-INHIBITOR | A61K2300/00; A61K31/427; A61K31/437; A61K31/4545; A61K31/4741; A61K31/4745; A61K45/06; A61K9/0019; A61K9/0053; A61P1/00; A61P15/00; A61P35/00; A61P43/00 | September 12, 2022 |
| AU2021225683A1 | Application | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | A61K31/4545; A61K31/496; A61P25/00; A61P29/00; A61P35/00; A61P37/00; C07D471/04; C07D519/00 | September 01, 2022 |
| EP4048280A1 | Application | ZUSAMMENSETZUNGEN ZUR VORBEUGUNG ODER BEHANDLUNG CHRONISCHER OBSTRUKTIVER LUNGENERKRANKUNGEN (COPD) | A61K31/397; A61K31/40; A61K31/4427; A61K31/4439; A61K31/445; A61K31/4453; A61K31/4525; A61K31/453; A61K31/454; A61K31/4545; A61K31/495; A61K31/496; A61K31/506; A61K31/5375; A61K31/5377; A61K31/551; A61K31/5513; A61K31/553; A61K9/0053; A61P11/00 | August 31, 2022 |
| MY192630A | Grant | A NOVEL ANTI-C-MET ANTIBODY AND USE THEREOF | A61K2039/505; A61K2039/507; A61K38/00; A61K39/3955; C07K16/28; C07K16/2863; C07K2317/24; C07K2317/31; C07K2317/33; C07K2317/34; C07K2317/53; C07K2317/565; C07K2317/622; C07K2317/73; C07K2317/76; C07K2317/77; C07K2317/92; G01N2333/71; G01N2333/912; G01N33/574; G01N33/5748; G01N33/57492 | August 29, 2022 |
| US11420950B2 | Grant | Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same | A61P35/00; A61P37/00; A61P9/00; C07D211/18; C07D211/22; C07D211/54; C07D211/58; C07D211/62; C07D211/96; C07D213/36; C07D241/04; C07D295/205; C07D295/215; C07D471/10 | August 23, 2022 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer